Introduction to ADaM and What s new in ADaM

Similar documents
Introduction to ADaM standards

ADaM Compliance Starts with ADaM Specifications

ADaM for Medical Devices: Extending the Current ADaM Structures

How to write ADaM specifications like a ninja.

Riepilogo e Spazio Q&A

What is the ADAM OTHER Class of Datasets, and When Should it be Used? John Troxell, Data Standards Consulting

Implementing CDISC Using SAS. Full book available for purchase here.

Material covered in the Dec 2014 FDA Binding Guidances

Analysis Data Model Implementation Guide Version 1.1 (Draft) Prepared by the CDISC Analysis Data Model Team

DCDISC Users Group. Nate Freimark Omnicare Clinical Research Presented on

ADaM IG v1.1 & ADaM OCCDS v1.0. Dr. Silke Hochstaedter

Traceability in the ADaM Standard Ed Lombardi, SynteractHCR, Inc., Carlsbad, CA

The Benefits of Traceability Beyond Just From SDTM to ADaM in CDISC Standards Maggie Ci Jiang, Teva Pharmaceuticals, Great Valley, PA

Traceability Look for the source of your analysis results

From Implementing CDISC Using SAS. Full book available for purchase here. About This Book... xi About The Authors... xvii Acknowledgments...

Use of Traceability Chains in Study Data and Metadata for Regulatory Electronic Submission

Yes! The basic principles of ADaM are also best practice for our industry Yes! ADaM a standard with enforceable rules and recognized structures Yes!

CDASH Standards and EDC CRF Library. Guang-liang Wang September 18, Q3 DCDISC Meeting

An Efficient Solution to Efficacy ADaM Design and Implementation

Dealing with changing versions of SDTM and Controlled Terminology (CT)

Hands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania

Automate Analysis Results Metadata in the Define-XML v2.0. Hong Qi, Majdoub Haloui, Larry Wu, Gregory T Golm Merck & Co., Inc.

Improving Metadata Compliance and Assessing Quality Metrics with a Standards Library

ADaM and traceability: Chiesi experience

Clarifications About ADaM Implementation Provided in ADaMIG Version 1.1

Applying ADaM Principles in Developing a Response Analysis Dataset

Study Data Reviewer s Guide Completion Guideline

Hands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania Kim Minkalis, Accenture Life Sciences, Wayne, Pennsylvania

PharmaSUG Paper DS06 Designing and Tuning ADaM Datasets. Songhui ZHU, K&L Consulting Services, Fort Washington, PA

CDISC SDTM and ADaM Real World Issues

Xiangchen (Bob) Cui, Tathabbai Pakalapati, Qunming Dong Vertex Pharmaceuticals, Cambridge, MA

It s All About Getting the Source and Codelist Implementation Right for ADaM Define.xml v2.0

Programming checks: Reviewing the overall quality of the deliverables without parallel programming

ADaM Reviewer s Guide Interpretation and Implementation

DIA 11234: CDER Data Standards Common Issues Document webinar questions

Creating an ADaM Data Set for Correlation Analyses

AUTOMATED CREATION OF SUBMISSION-READY ARTIFACTS SILAS MCKEE

ADaM Implementation Guide Prepared by the CDISC ADaM Team

Optimization of the traceability when applying an ADaM Parallel Conversion Method

A Taste of SDTM in Real Time

PharmaSUG2014 Paper DS09

Some Considerations When Designing ADaM Datasets

Working with Composite Endpoints: Constructing Analysis Data Pushpa Saranadasa, Merck & Co., Inc., Upper Gwynedd, PA

The Implementation of Display Auto-Generation with Analysis Results Metadata Driven Method

NCI/CDISC or User Specified CT

ADaM Implementation Guide Status Update

Sandra Minjoe, Accenture Life Sciences John Brega, PharmaStat. PharmaSUG Single Day Event San Francisco Bay Area

esubmission - Are you really Compliant?

ABSTRACT INTRODUCTION WHERE TO START? 1. DATA CHECK FOR CONSISTENCIES

Harmonizing CDISC Data Standards across Companies: A Practical Overview with Examples

Dataset-XML - A New CDISC Standard

SDTM Implementation Guide Clear as Mud: Strategies for Developing Consistent Company Standards

Why organizations need MDR system to manage clinical metadata?

Deriving Rows in CDISC ADaM BDS Datasets

PharmaSUG Paper PO22

Beyond OpenCDISC: Using Define.xml Metadata to Ensure End-to-End Submission Integrity. John Brega Linda Collins PharmaStat LLC

Comparison of FDA and PMDA Requirements for Electronic Submission of Study Data

Advanced Data Visualization using TIBCO Spotfire and SAS using SDTM. Ajay Gupta, PPD

Paper FC02. SDTM, Plus or Minus. Barry R. Cohen, Octagon Research Solutions, Wayne, PA

Paper DS07 PhUSE 2017 CDISC Transport Standards - A Glance. Giri Balasubramanian, PRA Health Sciences Edwin Ponraj Thangarajan, PRA Health Sciences

STUDY DATA TECHNICAL CONFORMANCE GUIDE

Automated Creation of Submission-Ready Artifacts Silas McKee, Accenture, Pennsylvania, USA Lourdes Devenney, Accenture, Pennsylvania, USA

Leveraging ADaM Principles to Make Analysis Database and Table Programming More Efficient Andrew L Hulme, PPD, Kansas City, MO

PharmaSUG Paper DS24

SDTM-ETL TM. New features in version 1.6. Author: Jozef Aerts XML4Pharma July SDTM-ETL TM : New features in v.1.6

CDASH MODEL 1.0 AND CDASHIG 2.0. Kathleen Mellars Special Thanks to the CDASH Model and CDASHIG Teams

Managing CDISC version changes: how & when to implement? Presented by Lauren Shinaberry, Project Manager Business & Decision Life Sciences

Edwin Ponraj Thangarajan, PRA Health Sciences, Chennai, India Giri Balasubramanian, PRA Health Sciences, Chennai, India

Avoiding Sinkholes: Common Mistakes During ADaM Data Set Implementation

Pharmaceuticals, Health Care, and Life Sciences. An Approach to CDISC SDTM Implementation for Clinical Trials Data

Revision of Technical Conformance Guide on Electronic Study Data Submissions

Optimization of the traceability when applying an ADaM Parallel Conversion Method

Clinical Metadata Metadata management with a CDISC mindset

Codelists Here, Versions There, Controlled Terminology Everywhere Shelley Dunn, Regulus Therapeutics, San Diego, California

Customer oriented CDISC implementation

Lex Jansen Octagon Research Solutions, Inc.

The Wonderful World of Define.xml.. Practical Uses Today. Mark Wheeldon, CEO, Formedix DC User Group, Washington, 9 th December 2008

Pooling Clinical Data: Key points and Pitfalls. October 16, 2012 Phuse 2012 conference, Budapest Florence Buchheit

Legacy to SDTM Conversion Workshop: Tools and Techniques

Cost-Benefit Analysis of Retrospective vs. Prospective Data Standardization

Creating Define-XML v2 with the SAS Clinical Standards Toolkit 1.6 Lex Jansen, SAS

SAS Application to Automate a Comprehensive Review of DEFINE and All of its Components

PMDA Valida+on Rules. Preparing for your next submission to Japanese Pharmaceu6cals and Medical Devices Agency. Max Kanevsky December 10, 2015

How to handle different versions of SDTM & DEFINE generation in a Single Study?

Common Programming Errors in CDISC Data

PharmaSUG Paper PO21

Study Data Reviewer s Guide

Reporting & Visualisation : D un Dun standard maison au format CDISC 02/02/2016 CDISC GUF 1

Challenges with the interpreta/on of CDISC - Who can we trust?

Module I: Clinical Trials a Practical Guide to Design, Analysis, and Reporting 1. Fundamentals of Trial Design

Business & Decision Life Sciences

CRF Design for Data Standards. David A. Scocca

Standardizing FDA Data to Improve Success in Pediatric Drug Development

CDISC Standards and the Semantic Web

Creating Define-XML version 2 including Analysis Results Metadata with the SAS Clinical Standards Toolkit

Planning to Pool SDTM by Creating and Maintaining a Sponsor-Specific Controlled Terminology Database

Interpreting CDISC ADaM IG through Users Interpretation

PharmaSUG DS05

Doctor's Prescription to Re-engineer Process of Pinnacle 21 Community Version Friendly ADaM Development

SAS offers technology to facilitate working with CDISC standards : the metadata perspective.

Transcription:

Introduction to ADaM and What s new in ADaM Italian CDISC UN Day - Milan 27 th October 2017 Silvia Faini Principal Statistical Programmer CROS NT - Verona

ADaM Purpose Why are standards needed in analysis datasets? support an efficient generation allow analysis replication support the review of analysis results This is the aim of CDISC Analysis Data Model (ADaM): provide a framework to statistical programmers and statisticians that enables analysis of the data; allowing reviewers and other recipients of the data to have a clear understanding of the data s lineage from collection to analysis to results.

ADaM Motivation The marketing approval process for regulated human health products often includes the submission of data from clinical trials to the regulatory agencies, currently: FDA and PMDA require CDISC standards EMA and China FDA recommend CDISC standards For CDISC ADaM the following crucial items provide a roadmap for the reviewer: ADaM Compliant Datasets Define.xml Analysis Data Reviewer s Guide (ADRG): This document is mandatory and its contents integrate the information provided in define.xml and other document. A template, completing instructions and sample files created by a CSS/PhUSE working group http://www.phusewiki.org/wiki/index.php?title=analysis_data_reviewer%27s_g uide

ADaM Fundamental Principles Analysis datasets and their associated metadata must: facilitate clear and unambiguous communication provide traceability between the analysis data and its source data (ultimately SDTM) be readily useable by commonly available software tools (XPT, XML) Analysis datasets must: be accompanied by metadata Focus be analysis-ready one proc away

ADaM Metadata Metadata are a key component of ADaM, help to document, are one of the 2 levels of traceability Define.xml is the document which provides the 4 components of the ADaM metadata: Analysis datasets metadata Analysis variable metadata Parameter value-level metadata Analysis Results Metadata (ARM) Analysis variable

ADaM Traceability 1/2 Metadata traceability enables the user to understand the relationship: of the analysis variable to its source dataset and variable and is required for ADaM compliance; but also between an analysis result (e.g., a p-value) and analysis dataset. How? By describing the algorithm used or steps taken to derive or populate an analysis value from its immediate predecessor. Data point traceability enables the user to go directly to the specific predecessor record(s): When? Implemented if practically feasible. How? By providing clear links in the data (e.g. use of SRCDOM, SRCVAR, SRCSEQ variables) to the specific data values used as input for an analysis value.

ADaM Traceability 2/2 When traceability is successfully implemented, reviewers are able to identify: information that exists in the submitted SDTM study tabulation data information that is derived or imputed within the ADaM analysis dataset the method used to create derived or imputed data information used for analyses, in contrast to information that is not used for analyses yet is included to support traceability or future analysis

ADaM Define.xml

ADaM Define.xml

ADaM Define.xml

ADaM Define.xml

ADaM Define.xml

Analysis variable metadata ADaM Define.xml

ADaM Define.xml Analysis variable metadata

ADaM Define.xml

ADaM Define.xml

ADaM Define.xml

ADaM References ADaM Document Date Published Analysis Data Model (ADaM) v2.1 December 2009 Analysis Data Model Implementation Guide (ADaMIG) v1.1* February 2016 ADaM Examples in Commonly Used Statistical Analysis Methods v1.0 December 2011 The ADaM Basic Data Structure for Time-to-Event Analyses v1.0 May 2012 ADaM Data Structure for Adverse Event Analysis v1.0** May 2012 ADaM Structure for Occurrence Data (OCCDS) v1.0 February 2016 CDISC ADaM Validation Checks v1.3 March 2015 Define-XML v2.0 March 2013 Analysis Results Metadata Specification for Define-XML Version 2 v1.0 January 2015 *Enhancement of ADaMIG v1.0 **Superseded by OCCDS v1.0

ADaM Implementation 1/2 Analysis datasets must: include a subject-level analysis dataset named ADSL consist of the optimum number of analysis datasets needed and have enough self-sufficiency to allow analysis and review with little or no additional programming or data processing be named using the convention ADxxxxxx use ADaM standard variable names and naming conventions when available maintain the values and attributes of SDTM variables if copied into analysis datasets without renaming (i.e., adhere to the same name, same meaning, same values principle of harmonization) apply naming conventions for datasets and variables consistently across studies within a given submission and across multiple submissions for a product

ADaM Implementation 2/2 From ADaMIG v1.1 and OCCDS v1.0 there are 3 defined structures Subject Level Structure (ADSL) Reserved dataset name ADSL One record per subject, regardless of study design Basic Data Structure (BDS) Designed with the majority of analysis files in mind One or more records per subject per analysis parameter, per analysis time point (if applicable) Occurrence Data Structure (OCCDS) Designed specifically for counting occurrences More general version of the old ADAE document

ADSL 1/2 ADSL contains required variables such as subject-level population flags, planned and actual treatment variables, demographic information, randomization factors, subgrouping variables, and important dates. ADSL contains also other subject-level variables that are important in describing a subject s experience in the trial, e.g.: Baseline characteristics, Numeric equivalents of flags, Stratification variables, Treatment duration and compliance variables, Other key visit dates and durations, Protocol specific event information, such as death/survival This structure allows merging with any other dataset, including ADaM and SDTM datasets. ADSL is a source for subject-level variables used in other ADaM datasets, such as population flags and treatment variables. It should be noted that there is no requirement that every ADSL variable be copied into a BDS dataset.

ADSL 2/2

Basic Data Structure 1/2 A record in an ADaM dataset can represent an observed (e.g. predecessor in SDTM), derived (e.g. total score of a questionnaire), or imputed (e.g. LOCF) value required for analysis. A data value may be derived from any combination of SDTM and/or ADaM datasets. The BDS is flexible in that additional rows and columns can be added to support the analyses and provide traceability. In a study there is often more than one ADaM dataset that follows the BDS. The capability of adding rows and columns does not mean that everything should be forced into a single ADaM dataset. The optimum number of ADaM datasets should be designed for a study, as discussed in the ADaM model document.

Basic Data Structure 2/2

Occurrence Data Structure 1/4 Developed specifically for occurrence analysis: the counting of subjects with a given record or term Standard analyses of: Adverse Events Concomitant Medications Medical History Other possible use cases: Clinical Events, Procedures, Substance Use Protocol violations Inclusion/exclusion criteria occurrences and other uses depending on the analysis need

Occurrence Data Structure 2/4 Example of analysis needs Adverse Events

Occurrence Data Structure 3/4 Three Rules for OCCDS Use: 1. There is no need for AVAL or AVALC. There are typically one or more records for each occurrence assessment 2. Occurrence is (often) coded via a dictionary Typically includes a well-structured hierarchy of categories and terminology Re-mapping this hierarchy to BDS variables PARAM and generic *CAT variables would lose the structure and meaning of the dictionary 3. Data content is typically not modified for analysis There is no need for analysis versions of the variables that hold the dictionary hierarchy or category terms

Occurrence Data Structure 4/4 Determining When to Use OCCDS: Many (but not all) SDTM events and interventions class data are often analyzed as occurrences and thus should use OCCDS Note: exposure data (EX) is often best analyzed with BDS, creating multiple analysis parameters Lab events is an example of a findings SDTM class data analyzed as occurrences with OCCDS OCCDS is not designed for all categorical data Example: questionnaire responses would never be mapped to a hierarchical dictionary, fit nicely in BDS, and should not use OCCDS Choice of ADaM dataset structure always depends on analysis need

What s new? Basically ADaMIG v1.1 and OCCDS v1.0 Notable Enhancements in ADaMIG v1.1 in comparison to ADaMIG v1.0 OCCDS v1.0 versus ADAE v1.0 Therapeutic Area User Guide (TAUG)

Notable Enhancements in ADaMIG v1.1 Main emphasis: clarification of ADaMIG 1.0 throughout the document Useful new variables (e.g. AGEGRy - Pooled Age Group y) Clarified ADaM vs non-adam analysis datasets: to prevent confusion for non-adam use as two-letter prefix "AX" Tables of variable name fragments (e.g. FL, DT, CHG, GRy, FU) Length of copied SDTM variables can be reduced to maximum length of actual values to optimize file size (e.g. remove trailing blanks) New w-index in variable names PARAM is the only variable that describes AVAL or AVALC. Qualifiers are not allowed. ADaM BDS is different from a SDTM Finding domain Expanded SRCDOM to allow ADaM dataset names, SRCSEQ to refer to new variable ASEQ

OCCDS vs ADAE OCCDS added variables not applicable to AEs Example: WHO-Drug hierarchy

Therapeutic Area User Guide (TAUG) ADaM Terminology SDTM CDASH ADaM